Global Infectious Disease Diagnostics Market
Historic Period: 2020–2024
Base Year: 2025
Estimated Year: 2026
Forecast Period: 2026–2036
Market Overview
The global Infectious Disease Diagnostics Market is experiencing robust growth driven by increasing prevalence of viral and bacterial infections, rising demand for rapid diagnostic solutions, and advancements in molecular testing technologies. The market has evolved significantly with the expansion of point-of-care (POC) diagnostics, real-time PCR platforms, and next-generation sequencing (NGS)-based pathogen identification.
Government initiatives for early disease detection, pandemic preparedness strategies, and increased healthcare spending in emerging economies continue to support market expansion. The shift toward decentralized testing and automated laboratory systems is reshaping competitive dynamics.
Market Segmentation Analysis
By Product & Service
1. Assays
-
ELISA-based assays
-
Rapid diagnostic tests (RDTs)
-
Multiplex assays
-
Lateral flow assays
2. Kits & Reagents
-
PCR reagent kits
-
Nucleic acid extraction kits
-
Antigen & antibody detection kits
-
Control & calibration reagents
3. Instruments
-
PCR systems
-
Automated immunoassay analyzers
-
NGS platforms
-
Microbiology analyzers
-
Point-of-care testing devices
By Disease Type
-
Hepatitis (A, B, C)
-
HIV/AIDS
-
Hospital-Acquired Infections (HAIs)
-
Human Papillomavirus (HPV)
-
Tuberculosis (TB)
-
Influenza
-
COVID-19 (New Segment)
-
Dengue & Malaria (New Segment)
-
Sepsis (New Segment)
By Technology
1. Immunodiagnostics
-
ELISA
-
Chemiluminescence Immunoassay (CLIA)
-
Rapid Antigen Testing
2. Polymerase Chain Reaction (PCR)
-
Real-Time PCR
-
Digital PCR
-
Multiplex PCR
3. Next-Generation Sequencing (NGS)
-
Whole Genome Sequencing
-
Targeted Sequencing Panels
4. Isothermal Nucleic Acid Amplification (New Segment)
-
LAMP (Loop-mediated Isothermal Amplification)
-
Recombinase Polymerase Amplification (RPA)
By End User
-
Hospitals
-
Diagnostic Laboratories
-
Research Institutes
-
Public Health Laboratories (New Segment)
-
Academic Institutions
Regional Analysis
North America
North America dominates the market due to advanced healthcare infrastructure, strong regulatory frameworks, and high adoption of molecular diagnostics. The U.S. leads in innovation, supported by significant R&D investments and pandemic preparedness initiatives.
Western Europe
Western Europe shows steady growth driven by public healthcare funding, robust laboratory networks, and high screening rates for infectious diseases.
Asia Pacific
Asia Pacific is expected to witness the fastest growth. Increasing disease burden, expanding diagnostic infrastructure, and government-led screening programs in China and India are key growth drivers.
Eastern Europe
Gradual growth supported by modernization of laboratory facilities and increased public health spending.
Middle East
Market expansion driven by healthcare infrastructure development and government initiatives targeting infectious disease control.
Rest of the World
Latin America and Africa present growth opportunities due to high prevalence of infectious diseases and expanding access to diagnostic services.
Key Market Players
-
Abbott Laboratories
-
Becton, Dickinson and Company
-
bioMérieux SA
-
Bio-Rad Laboratories, Inc.
-
F. Hoffmann-La Roche Ltd
-
Thermo Fisher Scientific Inc.
-
Danaher Corporation
-
QIAGEN N.V.
-
Hologic, Inc.
-
Siemens Healthineers
Porter’s Five Forces Analysis
1. Threat of New Entrants – Moderate
Regulatory approvals and capital investment create entry barriers; however, biotech startups in molecular diagnostics are increasing.
2. Bargaining Power of Suppliers – Moderate
Specialized reagent and raw material suppliers exert influence, particularly for nucleic acid amplification kits.
3. Bargaining Power of Buyers – High
Hospitals and centralized laboratories negotiate volume-based pricing contracts.
4. Threat of Substitutes – Low
Limited alternatives to laboratory-confirmed diagnostics for infectious disease detection.
5. Competitive Rivalry – High
Intense competition among multinational diagnostic companies with continuous innovation and product launches.
SWOT Analysis
Strengths
-
High demand for rapid and accurate diagnostics
-
Strong government support for disease surveillance
-
Technological advancements in molecular testing
Weaknesses
-
High cost of advanced molecular platforms
-
Regulatory compliance complexity
-
Dependence on supply chain for reagents
Opportunities
-
Expansion of point-of-care testing
-
Integration of AI for diagnostic interpretation
-
Growing demand in emerging markets
-
Development of multiplex and syndromic panels
Threats
-
Pricing pressure
-
Patent expiration risks
-
Supply chain disruptions
-
Changing regulatory landscapes
Market Drivers
-
Rising global infectious disease burden
-
Growing need for early disease detection
-
Increasing adoption of molecular diagnostics
-
Government-funded screening programs
-
Expansion of decentralized testing
Market Challenges
-
Limited infrastructure in low-income regions
-
Skilled workforce shortages
-
High instrument acquisition costs
-
Reimbursement limitations
Trend Analysis
-
Shift toward decentralized and point-of-care diagnostics
-
Growth in multiplex PCR testing
-
Adoption of digital PCR for precision diagnostics
-
Expansion of syndromic testing panels
-
Integration of cloud-based laboratory information systems
Value Chain Analysis
Raw Material Suppliers → Reagent Manufacturers → Instrument Manufacturers → Distributors → Laboratories/Hospitals → Patients
Key value addition occurs in:
-
Assay development & validation
-
Platform automation
-
Regulatory approval
-
Post-sales technical support
Competitive Landscape Overview
The market is moderately consolidated, dominated by multinational diagnostics corporations with extensive distribution networks. Strategic initiatives include:
-
Mergers & acquisitions
-
Development of rapid molecular testing platforms
-
Geographic expansion into emerging markets
-
Public-private partnerships for disease surveillance
Quick Strategic Recommendations
For Manufacturers
-
Invest in multiplex and syndromic testing solutions
-
Expand affordable POC diagnostics in emerging markets
-
Strengthen supply chain resilience
For Investors
-
Target molecular diagnostics startups
-
Focus on Asia Pacific expansion opportunities
For Healthcare Providers
-
Adopt automated molecular platforms
-
Integrate AI-driven data interpretation
For Governments & Public Health Agencies
-
Strengthen disease surveillance programs
-
Promote local manufacturing of diagnostic kits
TABLE OF CONTENTS
1 MARKET ABSTRACT
2 MARKET INTRODUCTION
2.1 MARKET SCOPE
2.2 MARKET PROPERTIES/ BEHAVIOR
2.3 KEY DEFINITIONS–CONTENT
3 QMI RESEARCH PRACTICE
3.1 RESEARCH PRACTICE
3.1.1 GLOBAL LEVEL ANALYSIS
3.1.2 COUNTRY LEVEL ANALYSIS
3.1.3 SUPPLY SIDE ANALYSIS
3.1.4 DEMAND SIDE ANALYSIS
3.1.5 TRIANGULATION
3.2 PRIMARY DATA
3.3 SECONDARY DATA
3.4 MARKET EVALUATION & FORECASTING METHODOLOGY
3.5 ASSUMPTIONS/ LIMITATIONS FOR THE STUDY
3.6 WHAT THIS STUDY PROVIDES
3.7 KEY QUESTIONS ANSWERED BY THIS REPORT
3.8 THIS STUDY IS INTENDED FOR
4 KEY RELATED DATA
4.1 COMPETITIVE POSITIONING
4.1.1 PRODUCT POSITIONING
4.1.2 REVENUE POSITIONING
4.1.3 REGIONAL REACH POSITIONING
4.2 VENDOR MATRIX
4.3 PATENTS
4.4 TECHNOLOGICAL ADVANCEMENTS
4.5 CUSTOMER ANALYSIS
5 IMPACT FACTOR ANALYSIS
5.1 MICRO ECONOMIC POINTERS
5.2 MACRO ECONOMIC POINTERS
5.3 PORTER’S FIVE FORCE MODEL/ PESTLE ANALYSIS/ VALUE CHAIN ANALYSIS
5.4 DRIVERS/RESTRAINTS/OPPORTUNITIES/CHALLENGES
6 MARKET DEVELOPMENT ANALYSIS
6.1 NEW PRODUCT DEVELOPMENT/ LAUNCH
6.2 MERGERS AND ACQUISITIONS
6.3 PARTNERSHIPS / AGREEMENTS/COLLABORATIONS
7 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT&SERVICES
7.1 INTRODUCTION
7.2 MARKET SHARE ANALYSIS
7.3 ASSAY
7.4 KIT & REAGENT
7.5 INSTRUMENTS
8 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE
8.1 INTRODUCTION
8.2 MARKET SHARE ANALYSIS
8.3 HEPATITIS
8.4 HIV
8.5 HAI
8.6 HPV
8.7 TB
8.8 INFLUENZA
9 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY
9.1 INTRODUCTION
9.2 MARKET SHARE ANALYSIS
9.3 PCR
9.4 NGS
9.5 IMMUNODIAGNOSTICS
10 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER
10.1 INTRODUCTION
10.2 MARKET SHARE ANALYSIS
10.3 RESEARCH INSTITUTE
10.4 HOSPITALS
11 INFECTIOUS DISEASE DIAGNOSTICS MARKET, REGIONAL ANALYSIS
11.1 INTRODUCTION
11.2 NORTH AMERICA INFECTIOUS DISEASE DIAGNOSTICS MARKET
11.2.1 NORTH AMERICA INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY COUNTRY
11.2.1.1 US Infectious Disease Diagnostics Market
11.2.1.2 Canada Infectious Disease Diagnostics Market
11.2.1.3 Mexico Infectious Disease Diagnostics Market
11.2.2 NORTH AMERICA INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT&SERVICE
11.2.3 NORTH AMERICA INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE
11.2.4 NORTH AMERICA INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY
11.2.5 NORTH AMERICA INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER
11.3 WESTERN EUROPE INFECTIOUS DISEASE DIAGNOSTICS MARKET
11.3.1 WESTERN EUROPE INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY COUNTRY
11.3.1.1 Germany Infectious Disease Diagnostics Market
11.3.1.2 UK Infectious Disease Diagnostics Market
11.3.1.3 France Infectious Disease Diagnostics Market
11.3.1.4 Italy Infectious Disease Diagnostics Market
11.3.1.5 Spain Infectious Disease Diagnostics Market
11.3.1.6 Rest of Western Europe Infectious Disease Diagnostics Market
11.3.2 WESTERN EUROPE INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT&SERVICE
11.3.3 WESTERN EUROPE INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE
11.3.4 WESTERN EUROPE INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY
11.3.5 WESTERN EUROPE INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER
11.4 EASTERN EUROPE INFECTIOUS DISEASE DIAGNOSTICS MARKET
11.4.1 EASTERN EUROPE INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY COUNTRY
11.4.1.1 Russia Infectious Disease Diagnostics Market
11.4.1.2 Turkey Infectious Disease Diagnostics Market
11.4.1.3 Rest of Eastern Europe Infectious Disease Diagnostics Market
11.4.2 EASTERN EUROPE INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT&SERVICE
11.4.3 EASTERN EUROPE INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE
11.4.4 EASTERN EUROPE INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLGY
11.4.5 EASTERN EUROPE INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER
11.5 ASIA PACIFIC INFECTIOUS DISEASE DIAGNOSTICS MARKET
11.5.1 ASIA PACIFIC INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY COUNTRY
11.5.1.1 China Infectious Disease Diagnostics Market
11.5.1.2 Japan Infectious Disease Diagnostics Market
11.5.1.3 India Infectious Disease Diagnostics Market
11.5.1.4 South Korea Infectious Disease Diagnostics Market
11.5.1.5 Australia Infectious Disease Diagnostics Market
11.5.1.6 Taiwan Infectious Disease Diagnostics Market
11.5.1.7 Malaysia Infectious Disease Diagnostics Market
11.5.1.8 Indonesia Infectious Disease Diagnostics Market
11.5.1.10 Rest of Asia Pacific Infectious Disease Diagnostics Market
11.5.2 ASIA PACIFIC INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT&SERVICE
11.5.3 ASIA PACIFIC INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE
11.5.4 ASIA PACIFIC INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY
11.5.5 ASIA PACIFIC INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER
11.6 MIDDLE EAST INFECTIOUS DISEASE DIAGNOSTICS MARKET
11.6.1 MIDDLE EAST INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY COUNTRY
11.6.1.1 UAE Infectious Disease Diagnostics Market
11.6.1.2 Saudi Arabia Infectious Disease Diagnostics Market
11.6.1.3 Qatar Infectious Disease Diagnostics Market
11.6.1.4 Iran Infectious Disease Diagnostics Market
11.6.1.5 Rest of Middle East Infectious Disease Diagnostics Market
11.6.2 MIDDLE EAST INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT&SERVICE
11.6.3 MIDDLE EAST INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE
11.6.4 MIDDLE EAST INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLGY
11.6.5 MIDDLE EAST INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER
11.7 REST OF THE WORLD INFECTIOUS DISEASE DIAGNOSTICS MARKET
11.7.1 REST OF THE WORLD INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY REGION
11.7.1.1 South America (Brazil, Argentina, Colombia, Others) Infectious Disease Diagnostics Market
11.7.1.2 Africa (Nigeria, South Africa, Others) Infectious Disease Diagnostics Market
11.7.2 REST OF THE WORLD INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT&SERVICE
11.7.3 REST OF THE WORLD INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE
11.7.4 REST OF THE WORLD INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLGY
11.7.5 REST OF THE WORLD INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER
12 INFECTIOUS DISEASE DIAGNOSTICS MARKET, COMPANY ANALYSIS
12.1 Abbott Laboratories
12.1.1 FINANCIAL OVERVIEW
12.1.2 PRODUCT/SOLUTION OVERVIEW
12.1.3 SWOT ANALYSIS
12.1.4 KEY DEVELOPMENTS
12.2 BECTON.
12.3 BIOMERIEUX
12.4 BIO-RAD
12.5 ROCHE
*Financials and Details May Not be Included in Case of Privately Held Company
13 INFECTIOUS DISEASE DIAGNOSTICS MARKET: CONCLUSION
13.1 INFECTIOUS DISEASE DIAGNOSTICS MARKET SNAPSHOT
13.2 INFECTIOUS DISEASE DIAGNOSTICS MARKET PROSPECTS- BY PRODUCT&SERVICES
13.3 INFECTIOUS DISEASE DIAGNOSTICS MARKET PROSPECTS- BY DISEASE TYPE
13.4 INFECTIOUS DISEASE DIAGNOSTICS MARKET PROSPECTS- BY TECHNOLGY
13.5 INFECTIOUS DISEASE DIAGNOSTICS MARKET PROSPECTS- BY END USER
14 APPENDIX
14.1 LIST OF ABBREVIATION
14.2 ADDITIONAL DEVELOPMENTS
14.3 RELATED REPORTS
Market Segmentation Analysis
By Product & Service
1. Assays
-
ELISA-based assays
-
Rapid diagnostic tests (RDTs)
-
Multiplex assays
-
Lateral flow assays
2. Kits & Reagents
-
PCR reagent kits
-
Nucleic acid extraction kits
-
Antigen & antibody detection kits
-
Control & calibration reagents
3. Instruments
-
PCR systems
-
Automated immunoassay analyzers
-
NGS platforms
-
Microbiology analyzers
-
Point-of-care testing devices
By Disease Type
-
Hepatitis (A, B, C)
-
HIV/AIDS
-
Hospital-Acquired Infections (HAIs)
-
Human Papillomavirus (HPV)
-
Tuberculosis (TB)
-
Influenza
-
COVID-19 (New Segment)
-
Dengue & Malaria (New Segment)
-
Sepsis (New Segment)
By Technology
1. Immunodiagnostics
-
ELISA
-
Chemiluminescence Immunoassay (CLIA)
-
Rapid Antigen Testing
2. Polymerase Chain Reaction (PCR)
-
Real-Time PCR
-
Digital PCR
-
Multiplex PCR
3. Next-Generation Sequencing (NGS)
-
Whole Genome Sequencing
-
Targeted Sequencing Panels
4. Isothermal Nucleic Acid Amplification (New Segment)
-
LAMP (Loop-mediated Isothermal Amplification)
-
Recombinase Polymerase Amplification (RPA)
By End User
-
Hospitals
-
Diagnostic Laboratories
-
Research Institutes
-
Public Health Laboratories (New Segment)
-
Academic Institutions
